For Immediate Release

2017.01.10

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: George Nakayama, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Executive Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com

Daiichi Sankyo Announces Reorganization of Research & Development System

Tokyo, Japan (January 10, 2017)- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced its decision to close its research subsidiary, Daiichi Sankyo India Pharma Private Limited (location: Gurgaon, India; hereafter, DSIN), to increase R&D productivity.

Daiichi Sankyo is reviewing its global R&D system with the aim of decreasing R&D operations costs and redistributing resources to the further development of its R&D pipeline.

DSIN presently employs approximately 170 people, mainly engaged in conducting drug discovery research targeting infectious diseases and inflammation. Following its closure, the DSIN R&D pipeline (including research themes selected by the Global Health Innovative Technology Fund [GHIT Fund]) will be transferred to Daiichi Sankyo's R&D Division.

Daiichi Sankyo Co. Ltd. published this content on 10 January 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 10 January 2017 01:08:03 UTC.

Original documenthttp://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/006562.html

Public permalinkhttp://www.publicnow.com/view/BB39850F9D4F472E6CD2924CEA10EF746A7A58CD